PhaseBio Pharmaceuticals Depreciation & Amortization

Depreciation & Amortization of PHAS for past 10 years: annual, quarterly and twelve month trailing (TTM) including Depreciation & Amortization growth rates and interactive chart.


Highlights and Quick Summary

  • Depreciation & Amortization for the quarter ending September 29, 2021 was $130 Thousand (a -77.7% decrease compared to previous quarter)
  • Year-over-year quarterly Depreciation & Amortization decreased by -61.99%
  • Annual Depreciation & Amortization for 2020 was $508 Thousand (a 191.95% increase from previous year)
  • Annual Depreciation & Amortization for 2019 was $174 Thousand (a 65.71% increase from previous year)
  • Annual Depreciation & Amortization for 2018 was $105 Thousand (a 9.38% increase from previous year)
  • Twelve month Depreciation & Amortization ending September 29, 2021 was $1.53 Million (a 5.16% increase compared to previous quarter)
  • Twelve month trailing Depreciation & Amortization increased by 200.98% year-over-year
Trailing Depreciation & Amortization for the last four month:
29 Sep '21 29 Jun '21 30 Mar '21 30 Dec '20
$1.53 Million $1.45 Million $928 Thousand $508 Thousand
Visit stockrow.com/PHAS for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Depreciation & Amortization of PhaseBio Pharmaceuticals

Most recent Depreciation & Amortizationof PHAS including historical data for past 10 years.

Interactive Chart of Depreciation & Amortization of PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals Depreciation & Amortization for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $0.13 $0.58 $0.47
2020 $0.34 $0.06 $0.06 $0.05 $0.51
2019 $0.05 $0.05 $0.04 $0.03 $0.17
2018 $0.02 $0.03 $0.03 $0.03 $0.11
2017 $0.03 $0.07 $0.1
2016 $0.09

Business Profile of PhaseBio Pharmaceuticals

Sector: Healthcare
Industry: Biotechnology
PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel for cardiopulmonary diseases. Its lead product candidate is bentracimab (PB2452), a reversal agent for the antiplatelet drug ticagrelor that is in Phase III clinical trial for patients with uncontrolled major or life-threatening bleeding events or in patients requiring urgent or emergency surgery. The company is also developing PB1046, a vasoactive intestinal peptide analogue that is in Phase IIb clinical trial for the treatment of pulmonary arterial hypertension; and PB6440 for the treatment of resistant hypertension. The company has a co-development agreement with SFJ Pharmaceuticals X, Ltd. to develop PB2452, a reversal agent for the antiplatelet drug ticagrelor. PhaseBio Pharmaceuticals, Inc. was incorporated in 2002 and is based in Malvern, Pennsylvania.